Follow-Up Appointment Guidelines After Initiating ADHD Medication in Adults

Initial Titration Phase (First 2-4 Weeks)

The American Academy of Child and Adolescent Psychiatry recommends maintaining weekly contact during dose adjustment, either by telephone or office visits, to optimize medication efficacy and monitor for adverse effects 1
The titration phase typically requires 2-4 weeks to identify the optimal dose that controls symptoms without intolerable side effects 1
For stimulants specifically, titration can be accomplished rapidly—as quickly as 3-7 days per dose adjustment in urgent situations, though weekly increments are standard 2
If using methylphenidate, increase in weekly increments of 5-10 mg per dose if symptom control is inadequate 1
For dextroamphetamine/amphetamine formulations, increase in weekly increments of 2.5-5 mg 1
Response to stimulants is idiosyncratic and unpredictable—calculating dose by body weight (mg/kg) is not helpful as variations are unrelated to height or weight 2

The American Academy of Child and Adolescent Psychiatry recommends scheduling follow-up appointments at least monthly until the patient's symptoms have been fully stabilized 1
Long-acting formulations are strongly preferred for adults due to better adherence, lower rebound risk, and more consistent symptom control 3
Systematically assess core ADHD symptoms (inattention, hyperactivity, impulsivity) using both patient self-ratings and collateral information from family/close contacts, as adults with ADHD are unreliable self-reporters 1, 3
Evaluate functional improvement across multiple domains (work, relationships, daily activities), not just symptom reduction 3
Ask specific questions about known side effects rather than general inquiries: insomnia, decreased appetite, headaches, anxiety/jitteriness, increased pulse, dry mouth, decreased sexual desire, and perspiration 1
Weigh the patient at each visit to objectively monitor appetite effects and weight changes 1, 4
Monitor vital signs (blood pressure and pulse) at each visit, as stimulants cause small but consistent increases (mean 2.4 mmHg systolic/diastolic, 3.2 bpm pulse increase) 3

Increase appointment frequency (more than monthly) if significant side effects emerge that require dose or timing adjustments 1
Increase appointment frequency if comorbid psychiatric conditions cause significant impairment 1
Increase appointment frequency if poor medication adherence is identified 1
Increase appointment frequency if patient requires additional psychoeducation about ADHD as a chronic condition 1
The American Academy of Pediatrics emphasizes that ADHD requires chronic disease management with consistent follow-up 2

For non-stimulant medications (atomoxetine), full therapeutic effect requires 6-12 weeks at target dose, with median response time of 3.7 weeks 4
Premature discontinuation before 6-12 weeks is a frequent error—patients must be counseled about delayed onset 4
Monitor blood pressure and heart rate at each dose adjustment for non-stimulant medications (atomoxetine) 4
Exercise particular caution and increase monitoring frequency when prescribing stimulants to adults with comorbid substance abuse disorder 3
Long-acting formulations like lisdexamfetamine or OROS methylphenidate have reduced abuse potential and are preferred in this population 3

Once stabilized, continue regular follow-up as ADHD is a chronic condition requiring ongoing management 2